Literature DB >> 102227

Antimicrobial drug usage in general hospitals in Pennsylvania.

E H Kass.   

Abstract

The Inter-Society Committee on Antimicrobial Drug Usage has conducted a survey of 20 randomly selected general hospitals in Pennsylvania. Records studied were of 5288 patients who either died or were discharged on 10 random days throughout 1974. About 28% of these patients received at least one antimicrobial drug during hospitalization. In 60% of the patients the drugs were given for treatment of infectious disease; in 30% they were given as prophylaxis for surgical or nonsurgical procedures. Prophylactic treatment was given for more than 2 days after a procedure in most cases, even though it is not considered effective after 48 h. Discontinuing prophylaxis after 48 h would reduce by 20% the use of antimicrobial drugs in hospitals. Overall, ampicillin and the cephalosporins were the most commonly prescribed drugs, with the more toxic drugs being used infrequently; over half of the patients given antimicrobial drugs had cultures taken. Both of these findings are consistent with accepted standards for antimicrobial drug usage.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 102227     DOI: 10.7326/0003-4819-89-5-800

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

1.  Antibiotic cost reduction by providing cost information.

Authors:  E Rubinstein; A Barzilai; S Segev; Y Samra; M Modan; O Dickerman; C Haklai
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Quality of use of parenteral metronidazole therapy in a teaching hospital.

Authors:  P J Jewesson; R L Bachand; G A Bell; R J Ensom; A W Chow
Journal:  Can Med Assoc J       Date:  1985-04-01       Impact factor: 8.262

3.  Prevalence of antimicrobial use and active healthcare-associated infections in acute care hospitals: a multicentre prevalence survey in Japan.

Authors:  Junpei Komagamine; Taku Yabuki; Masaki Kobayashi; Taro Okabe
Journal:  BMJ Open       Date:  2019-06-28       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.